Prevalence and Maintenance of Clinical Remission in Patients with Severe Uncontrolled Asthma Undergoing Biologic Therapies
Elena Dorado-Fonseca, Julia García de Pedro, Zichen Ji, Beatriz Recio-Moreno, Laura de Miguel-Rodríguez, María Jesús Buendía-García, Javier de Miguel-Díez · 2026
Read Prevalence and Maintenance of Clinical Remission in Patients with Severe Uncontrolled Asthma Undergoing Biologic Therapies by Elena Dorado-Fonseca, Julia García de Pedro, Zichen Ji, Beatriz Recio-Moreno, Laura de Miguel-Rodríguez, María Jesús Buendía-García, Javier de Miguel-Díez (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13634063.txt.
Description
Elena Dorado-Fonseca and six co-authors ask how often severe asthma truly remits on biologic drugs, and how long the calm lasts, in a 2026 study. Remission is a new goal in asthma care, but real-world staying power is unclear.
Fifty patients who started a first biologic between 2015 and 2019 were tracked. Remission at one year meant no flare-ups, good control scores, strong lung function, and no daily steroid pills. Thirteen patients, 26 percent, got there; they started with better lung capacity and control. Fewer than half of them, six, stayed in remission over about five years. The authors say the baseline clues need testing in larger groups.
Catalog record
| CREATOR | Elena Dorado-Fonseca, Julia García de Pedro, Zichen Ji, Beatriz Recio-Moreno, Laura de Miguel-Rodríguez, María Jesús Buendía-García, Javier de Miguel-Díez |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 13 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |